Compare IMMR & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | MIST |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 176.3M |
| IPO Year | 1999 | 2019 |
| Metric | IMMR | MIST |
|---|---|---|
| Price | $7.57 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.50 | $8.00 |
| AVG Volume (30 Days) | 513.2K | ★ 1.1M |
| Earning Date | 04-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $326.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $1.00 |
| 52 Week High | $7.50 | $3.06 |
| Indicator | IMMR | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 33.63 |
| Support Level | $6.31 | $1.00 |
| Resistance Level | N/A | $1.42 |
| Average True Range (ATR) | 0.29 | 0.06 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 85.61 | 2.63 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).